In Vitro Activity of Iclaprim against Isolates in Two Phase 3 Clinical Trials (REVIVE-1 and -2) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI).

In Vitro Activity of Iclaprim against Isolates in Two Phase 3 Clinical Trials (REVIVE-1 and -2) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
Antimicrob Agents Chemother. 2019 Jan 14;:
Authors: Noviello S, Magnet S, Hawser S, Huang DB
Abstract
Iclaprim, a selective bacterial dihydrofolate reductase inhibitor, and other antibiotics were tested against Gram-positive isolates from two Phase 3 studies of ABSSSI (REVIVE-1 and -2). Seven hundred-ninety baseline isolates, including S. aureus, beta-hemolytic streptococci, and S. anginosus Group, underwent antibacterial susceptibility testing. Iclaprim had MIC90 of 0.12μg/mL for S. aureus (0.12μg/mL for methicillin-susceptible, 0.25μg/mL for methicillin-resistant), 0.25μg/mL for beta-hemolytic streptococci and 0.008μg/mL for S. anginosus Group. Iclaprim demonstrated potent activity against these Gram-positive ABSSSI isolates.
PMID: 30642922 [PubMed - as supplied by publisher]

Source: Antimicrobial Agents and Chemotherapy - January 14, 2019 Category: Microbiology Authors: Noviello S, Magnet S, Hawser S, Huang DB Tags: Antimicrob Agents Chemother Source Type: research